利美尼定(Rilmenidine)是第一个(?)唑啉类抗高血压药,对轻、中度高血压患者有颇佳疗效。与其他中枢交感神经抑制剂不同,该药在常用剂量下无镇静作用,甚少有口干和嗜睡等中枢性不良反应,对血糖、血脂和肾功能无明显不良影响,不良反应少而轻微。本文就其临床研究作一概述。作用机理迄今对该药的确切降压机理尚未明了。大鼠左胸推动脉内注射微量的利美尼定即产生强大持久的降压效应,但10倍此剂量全身性给药时却无降压效应,提示该药系通过作 Rilmenidine is the first (?) Oxazoline antihypertensive and has been shown to be effective in patients with mild to moderate hypertension. Different from other central sympathetic nerve blockers, the drug has no sedative effect at the usual dosage, and has few central adverse reactions such as dry mouth and drowsiness. It has no obvious adverse effect on blood sugar, blood lipid and renal function with few and minor adverse reactions. This article gives an overview of its clinical research. The mechanism of action So far the exact mechanism of this drug is not yet clear buck. The rat left chest to promote intramuscular injection of a small amount of Limidine will produce a strong and lasting antihypertensive effect, but 10 times the dose of this system without systemic antihypertensive effect, suggesting that the drug through